Trials / Completed
CompletedNCT04205799
Cabozantinib for Advanced or Metastatic Cervical Carcinoma After Platinum Treatment Failure
A Phase II Study Assessing Safety and Efficacy of Cabozantinib for Advanced or Metastatic Cervical Carcinoma After Platinum Treatment Failure
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 57 (actual)
- Sponsor
- Centre Francois Baclesse · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Assess efficacy and safety of cabozantinib in monotherapy in advanced/metastatic cervical cancer (CC) after failure of platinum-based regimen treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cabozantinib | Cabozantinib will be administered at the daily dose of 60 mg given orally in a 4-week cycle. It will be continued without interruption until disease progression or discontinuation for any cause. |
Timeline
- Start date
- 2020-01-15
- Primary completion
- 2023-01-15
- Completion
- 2023-01-15
- First posted
- 2019-12-19
- Last updated
- 2023-02-13
Locations
8 sites across 1 country: France
Source: ClinicalTrials.gov record NCT04205799. Inclusion in this directory is not an endorsement.